Microsphere Fabrication via Solvent Evaporation/Extraction

RESOMER R 205 S is an amorphous, acid-terminated Poly(D,L-lactide) produced as a drug delivery grade with an inherent viscosity specification of 0.55–0.75 dL/g when measured at 0.1% w/v in chloroform at 25°C according to DIN EN ISO 1628-1:2021. In oil-in-water microsphere manufacturing, the higher end of this viscosity window is selected when slow solvent extraction and reduced initial burst are required, while the lower end is used when lower organic-phase viscosity improves the dispersion kinetics through a defined rotor-stator shear field. The organic phase is typically prepared at 10–30% w/v polymer in dichloromethane, with a drug-to-polymer ratio of 1:5–1:20 w/w depending on the dose requirement and the crystallinity of the active pharmaceutical ingredient. The continuous aqueous phase contains polyvinyl alcohol at 0.5–2.0% w/v, buffered to pH 5.0–6.5 to limit lactide hydrolysis during particle hardening. Compliance for parenteral microsphere intermediates is anchored to USP <88> Class VI biological reactivity testing, ISO 10993-5:2009 cytotoxicity assessment, and ICH Q3C residual solvent limits, with dichloromethane controlled to a parenteral permitted daily exposure of 6.0 mg/day for the finished dosage form. Residual monomer content and polymer uniformity are evaluated against ISO 13781:2017, while moisture content is controlled below 0.5% w/w by Karl Fischer titration per ISO 15512:2019.

On production-scale high-shear mixing lines, batch-to-batch particle size drift is most frequently linked to a drop in tip speed below 10 m/s when rotor-stator equipment such as the IKA T25 digital Ultra-Turrax with S25N-25G dispersion tool or the Silverson L5M-A is operated with insufficient speed or worn stators. Emulsification is typically executed at 6,500–24,000 rpm, generating a droplet population that is subsequently transferred into 5–10 volumes of aqueous extraction medium at 15–25°C to remove dichloromethane. Continuous-phase temperature excursions above 25°C can nucleate dichloromethane vapor at the droplet interface, causing microsphere rupture and elevated surface porosity. The terminal finished product types include sterile lyophilized microsphere vials for intramuscular or subcutaneous injection, reconstitution vials with water for injection, and dual-chamber syringe systems in which the polymer-drug matrix remains separate from the aqueous vehicle until use. For peptide and protein payloads, the same polymer is employed in water-in-oil-in-water double emulsion routes with an internal aqueous phase of 1–10% w/v active ingredient and osmolality adjusted to 280–320 mOsm/kg to reduce interfacial protein denaturation.

What Governs Molecular Weight Retention in Hot-Melt Extruded Drug-Eluting Implants?

Monolithic implant rods and pellets incorporating RESOMER R 205 S as the continuous matrix are manufactured by hot-melt extrusion in co-rotating twin-screw equipment with an L/D ratio of 25:1–40:1, such as the Leistritz ZSE 18 HP-PH or Thermo Fisher Pharma 11 twin-screw extruder, at barrel temperatures from 100–130°C, screw speeds from 50–200 rpm, and melt pressures from 20–80 bar. The amorphous glass transition of RESOMER R 205 S is observed at 50–55°C by differential scanning calorimetry per ISO 11357-2:2020, and processing above 130°C for extended residence times produces measurable chain scission because the acid-terminated chain end accelerates hydrolytic degradation in the presence of residual water. Drug loading is typically 10–50 wt%, with plasticizers such as triethyl citrate or polyethylene glycol 400 added at 0–10 wt% when drug load exceeds 30 wt% or when the extrudate requires downstream injection molding. Before extrusion, the polymer-drug blend is vacuum dried at 40–60 mbar and 25–40°C for 12–48 h to reduce moisture below 0.2% w/w; failure to meet this moisture threshold on a production line typically appears as torque reduction, melt viscosity decay, and an intrinsic viscosity drop exceeding 5% after a single pass when measured per DIN EN ISO 1628-1:2021. Basic free-base amine actives are incompatible at elevated melt temperature because base-catalyzed ester cleavage accelerates molecular weight reduction, and such formulations require either salt conversion or alternative encapsulation routes.

Regulatory qualification for the resulting implant intermediates follows ISO 10993-6:2016 for local effects after implantation, USP <88> Class VI testing, and ICH Q3C for residual extrusion solvents where applicable. In-process control on a production line includes torque monitoring, die-pressure recording, and strand diameter feedback, with die diameters between 1–5 mm used for rod feedstock and downstream cutting into 2–10 mm implant segments. The terminal finished product types include subcutaneously inserted rods, biodegradable pellets for intratumoral or subcutaneous placement, and preformed ocular inserts where the drug load and implant dimensions are adjusted to the target release duration. Injection molding of extruded pellets is limited to clamp forces below 500 kN and closed-loop shot sizes that preserve the polymer molecular weight distribution; residence time in the injection barrel above 5 min at 130°C is a known cause of melt discoloration and premature release-profile failure.

In Situ Depot Formation Requires Solvent Exchange Rate Control

Injectable in situ forming depot formulations are produced by dissolving RESOMER R 205 S in a water-miscible biocompatible solvent, most commonly N-methyl-2-pyrrolidone, dimethyl sulfoxide, or benzyl alcohol, at a polymer concentration of 10–40 wt% and a drug load of 1–20 wt%. The polymer-drug solution is mixed under overhead agitation at 100–500 rpm and 25–50°C for 12–48 h, then filtered through a 0.22 µm membrane or terminally sterilized with gamma irradiation up to 25 kGy depending on the solvent and active ingredient. In this route, the formulation addition ratio determines the depot-forming behavior: polymer concentrations below 10 wt% produce injectable solutions but reduce the precipitation rate and increase the initial drug diffusion burst, while concentrations above 40 wt% raise viscosity to levels that require 21G needle injection forces above 80 N, a threshold observed on production batch release testing for prefilled syringes. Solvent exchange kinetics at the implant-fluid interface create a polymer-rich skin that governs outward drug transport, and the release profile is therefore controlled by the polymer-to-solvent ratio, the solvent choice, and the aqueous phase flow rate rather than by polymer degradation alone.

The relevant compliance standards for this route include ICH Q3C for residual solvent control, with N-methyl-2-pyrrolidone assigned a permitted daily exposure of 5.3 mg/day as a Class 2 solvent, USP <1> for injectable dosage form development, USP <71> for sterility testing, and ISO 10993-6:2016 for local tissue response after depot injection. Production-scale filling lines for these formulations typically use single-use syringes or single-dose vials under aseptic conditions, with the terminal finished product types including prefilled syringes for subcutaneous injection, injectable depots for intra-articular or intramuscular administration, and sterile vial configurations intended for reconstitution or direct withdrawal. The operational boundary is residual solvent content: formulations using N-methyl-2-pyrrolidone cannot exceed the ICH Q3C concentration limit of 530 ppm in the final depot unless justified by toxicological data, and residual water must remain below 0.5% w/w during storage to avoid premature polymer hydrolysis before injection.

For nanoparticulate carrier development, RESOMER R 205 S is dissolved with the active agent in a water-miscible organic phase such as acetone or ethanol at a polymer concentration of 1–10 mg/mL and a drug-to-polymer ratio of 1:5–1:20 w/w, then introduced into an aqueous surfactant phase containing 0.1–0.5% w/v polyvinyl alcohol or poloxamer 188 under controlled flow through a 21G needle at 0.5–2.0 mL/min. The aqueous phase is maintained at 25–35°C and 300–800 rpm with an overhead stirrer, and the resulting nanosuspension is concentrated by rotary evaporation at 30–40°C and 150–250 mbar to remove the organic solvent before lyophilization with 2–10% w/v trehalose or sucrose as a cryoprotectant. Particle size distribution is measured by dynamic light scattering according to ISO 22412:2017, and sterile filtration is only feasible when the mean hydrodynamic diameter remains below 200 nm with a polydispersity index below 0.20. The terminal finished product types are lyophilized sterile cakes for reconstitution and sterile-filterable nanodispersions intended for intravenous or subcutaneous administration, with compliance anchored to ISO 10993-5:2009, USP <88>, and ICH Q3C for residual acetone as a Class 3 solvent.

In transdermal macromolecule delivery, dissolving microneedle arrays produced from RESOMER R 205 S eliminate post-administration sharps waste because the amorphous polymer matrix dissolves in the stratum corneum and interstitial fluid after insertion, releasing the active ingredient without a nondissolving backing layer. The polymer is dissolved at 20–30% w/w in acetone/ethanol 70:30 v/v with a drug load of 10–30% w/w, and the solution is cast into polydimethylsiloxane molds under vacuum at −80 kPa for 10–30 min to fill the microneedle tips, followed by drying at 25°C for 24–48 h and demolding under ambient conditions below 30% RH. Mechanical insertion reliability is measured with a TA.XT Plus texture analyzer equipped with a 50 N load cell, and production arrays are typically specified to achieve a fracture force above 0.1 N per needle; the amorphous, acid-terminated PLDL matrix has lower rigidity than semi-crystalline poly(L-lactide), so needle height and base thickness must be adjusted when the drug load exceeds 30% w/w. Relevant compliance testing includes ISO 10993-10:2010 for skin sensitization, ISO 10993-5:2009 for cytotoxicity, and USP <88> Class VI biological reactivity. Terminal finished product types include dissolving microneedle arrays for vaccine, peptide, or hormone delivery, and laminated transdermal patch configurations in which the microneedle array is joined to an adhesive backing.

When Electrospun Fibers Encapsulate Acid-Terminated Poly(D,L-lactide) for Perioperative Placement

Electrospinning operations using RESOMER R 205 S are confined to applications where low mechanical load and rapid fiber degradation are acceptable, because the amorphous acid-terminated PLDL matrix has lower tensile strength than semi-crystalline poly(L-lactide) and undergoes hydrolytic chain scission that reduces fiber integrity after implantation. The polymer solution is prepared at 5–15% w/w in dichloromethane/dimethylformamide 80:20 v/v, with a drug-to-polymer ratio of 1:10–1:5 w/w and conductivity adjusted to 1–10 µS/cm using tetrabutylammonium chloride when consistent fiber diameter is required. The solution is delivered through a syringe pump at 0.5–2.0 mL/h, with a spinneret-to-collector distance of 10–20 cm, an applied voltage of 18–25 kV, and a rotating drum collector operated at 500–2,000 rpm to orient the fiber mat. Fiber diameter measured by scanning electron microscopy typically falls in the 300–1500 nm range, and the residual solvent profile is controlled under ICH Q3C, with dimethylformamide limited to a parenteral permitted daily exposure of 8.8 mg/day and dichloromethane to 6.0 mg/day in the finished matrix. Regulatory qualification includes ISO 10993-5:2009 cytotoxicity testing, ISO 10993-10:2010 skin sensitization testing, and USP <88> Class VI evaluation. Published industrial monographs for this specific electrospun configuration are limited when compared with microsphere and extruded implant routes, so process validation protocols must include lot-specific residual solvent and molecular weight retention data rather than relying on generic electrospinning parameters. The terminal finished product types are drug-eluting fiber mats and perioperative delivery sheets for localized antibiotic or analgesic administration, with the operational boundary that the amorphous PLDL matrix is not suitable for load-bearing surgical mesh or long-term implantable textile structures.